Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 160
- Registration Number
- NCT01431053
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 13
- Registration Number
- NCT01385280
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 297
- Registration Number
- NCT01381874
Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
- Conditions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 12
- Registration Number
- NCT01331447
- Locations
- 🇺🇸
BioKinetic Clinical Applications, Inc., Springfield, Missouri, United States
Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions
- Conditions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 47
- Registration Number
- NCT01331434
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States
Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
- Conditions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 48
- Registration Number
- NCT01331421
- Locations
- 🇺🇸
BioKinetic Clinical Applications, Inc., Springfield, Missouri, United States
A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2012-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 398
- Registration Number
- NCT01305239
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 117
- Registration Number
- NCT01303679
- Locations
- 🇫🇷
BACHELOT, Lyon, France
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5018
- Registration Number
- NCT01272037
- Locations
- 🇺🇸
Mills-Peninsula Medical Center, Burlingame, California, United States
🇺🇸Dublin Hematology Oncology Care PC, Dublin, Georgia, United States
🇺🇸Piedmont Fayette Hospital, Fayetteville, Georgia, United States
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01240941
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.